PT - JOURNAL ARTICLE AU - Andréanne Morin AU - Emma E. Thompson AU - Britney A. Helling AU - Lyndsey E. Shorey-Kendrick AU - Pieter Faber AU - Tebeb Gebretsadik AU - Leonard B. Bacharier AU - Meyer Kattan AU - George T. O’Connor AU - Katherine Rivera-Spoljaric AU - Robert A. Wood AU - Kathleen C. Barnes AU - Rasika A. Mathias AU - Matthew C. Altman AU - Kasper Hansen AU - Cindy T. McEvoy AU - Eliot R. Spindel AU - Tina Hartert AU - Daniel J. Jackson AU - James E. Gern AU - Chris G. McKennan AU - Carole Ober AU - program collaborators for Environmental Influences on Child Health Outcomes and Children’s Respiratory and Environmental Workgroup TI - A Functional Genomics Pipeline to Identify High-Value CpG Dinucleotides in the Human Methylome AID - 10.1101/2022.05.19.22275204 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.19.22275204 4099 - http://medrxiv.org/content/early/2022/06/27/2022.05.19.22275204.short 4100 - http://medrxiv.org/content/early/2022/06/27/2022.05.19.22275204.full AB - DNA methylation of cytosines at CpG dinucleotides is a widespread epigenetic mark; but genome-wide variation has been relatively unexplored due to the limited representation of variable CpGs on commercial high-throughput arrays. To explore this hidden portion of the epigenome, we combined whole-genome bisulfite sequencing with in silico evidence of function to design a custom array of high-value CpGs. We focused these studies in airway epithelial cells from children with and without allergic asthma because these cells mediate the effects of inhaled microbes, pollution and allergens on asthma and allergic disease risk. Epigenome-wide association studies (EWAS) of allergic sensitization revealed enrichments for CpGs with intermediate methylation levels that were more likely to be correlated with the expression of their target genes and associated with allergic sensitization in children of diverse ancestries compared to CpGs on commercial arrays. Overall, our study revealed signature features of functional CpGs and unveiled a wealth of DNA methylation variation at functional CpG sites that have been ignored in previous EWAS.Competing Interest StatementL.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside the submitted work. G.T.O. has received consulting fees from Dicerna and Menarini unrelated to this work. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis, Regeneron, and Sanofi. K.C.B. is employed by Tempus Labs. M.C.A. has received consulting fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from GlaxoSmithKline and Regeneron and personal fees from Pfizer, Sanofi, AstraZeneca, and Vifor Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca and Meissa Vaccines Inc. and has stock options in Meissa Vaccines Inc.Funding StatementResearch reported in this publication was supported by the Environmental influences on Child Health Outcomes (ECHO) program, Office of The Director, National Institutes of Health, under Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core), UH3 OD023282 (COAST, INSPIRE, URECA) and UH3 OD023288 (VCSIP); and grants UM1 AI114271, UM1 AI160040, U19 AI62310, U19 AI095227, UL1 TR002243 P51 OD011092 and R01 HL104608.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of Boston University, Columbia University, Johns Hopkins, and Washington University (URECA), University of Wisconsin-Madison (COAST), Vanderbilt University School of Medicine (INSPIRE), and Oregon Health & Science University, PeaceHealth Southwest Medical Center, Wishard or Indiana University Hospitals (VCSIP) all gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are currently being made available at GEO and dbGaP.